Vesicare Ls (Solifenacin Succinate) Patent Expiration, LOE Window & CMS Spending

Vesicare Ls (Solifenacin Succinate) by Astellas Pharma: FDA Orange Book LOE 2031-05-18, 18 AB generics, $319K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN209529 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-05-18
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$319K
2024 Medicare Part D Spend$34K
2024 Medicaid Spend$285K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.